AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 159 filers reported holding AKERO THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $114,816 | -32.8% | 2,270 | -38.0% | 0.00% | – |
| Q2 2023 | $170,932 | +38.5% | 3,661 | +13.5% | 0.00% | – |
| Q1 2023 | $123,388 | -69.7% | 3,225 | -56.6% | 0.00% | -100.0% |
| Q4 2022 | $407,328 | +115.5% | 7,433 | +34.1% | 0.00% | – |
| Q3 2022 | $189,000 | +800.0% | 5,541 | +145.7% | 0.00% | – |
| Q2 2022 | $21,000 | +5.0% | 2,255 | +63.9% | 0.00% | – |
| Q1 2022 | $20,000 | -13.0% | 1,376 | +25.1% | 0.00% | – |
| Q4 2021 | $23,000 | -8.0% | 1,100 | 0.0% | 0.00% | – |
| Q3 2021 | $25,000 | -66.7% | 1,100 | -63.7% | 0.00% | – |
| Q2 2021 | $75,000 | -35.3% | 3,031 | -24.2% | 0.00% | – |
| Q1 2021 | $116,000 | +510.5% | 4,000 | +433.3% | 0.00% | – |
| Q2 2020 | $19,000 | +18.8% | 750 | 0.0% | 0.00% | – |
| Q1 2020 | $16,000 | – | 750 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |